Brepocitinib Shows Promise for Cutaneous Sarcoidosis in Phase 2 Trial

Patients with cutaneous sarcoidosis – a rare inflammatory skin disease affecting an estimated 40,000 adults in the United States – experienced significant clinical and quality-of-life improvements in a phase 2 study evaluating the investigational drug brepocitinib. The findings, released on February 6, 2026, offer a potential new treatment option for a condition currently managed with prolonged use of off-label corticosteroids, immunosuppressants, or biologics, often with limited success and cumulative toxicity.

Sarcoidosis is a granulomatous disease that can affect multiple organs, with the lungs, skin, and eyes being the most frequently involved, according to Misha Rosenbach, MD, professor of dermatology and rheumatology and director of the Sarcoidosis Clinic at the Hospital of the University of Pennsylvania.

The BEACON Trial: A Closer Look

The phase 2 BEACON (Brepocitinib Efficacy And Cutaneous Sarcoidosis – Activity) study involved 31 adults with active cutaneous sarcoidosis. Participants were randomly assigned to receive either brepocitinib 45 mg (n=13), brepocitinib 15 mg (n=11), or a placebo (n=7) once daily for 16 weeks. The study, conducted across 15 US sites, utilized the Cutaneous Sarcoidosis Activity and Morphology Instrument – Activity (CSAMI-A) as a primary endpoint, measuring inflammatory lesion activity.

Participants had a CSAMI-A score of 10 or higher at baseline, with a mean age ranging from 49.4 to 58.7 years across the treatment groups. Notably, those receiving the 45 mg dose of brepocitinib had longer-standing disease, greater skin damage, and a higher prevalence of plaque-predominant morphology compared to the 15 mg group.

Significant Improvements Observed with Brepocitinib

At week 16, participants in the brepocitinib 45 mg group demonstrated a mean CSAMI-A improvement of -22.3 points from baseline, compared to -0.7 points in the placebo group (P < .0001). This substantial difference was statistically significant and became apparent as early as weeks 4, and 6. A remarkable 62% of patients in the 45 mg group achieved functional remission, defined as a CSAMI-A score of less than 5, compared to 0% in the placebo group (P = .0147).

Improvements extended beyond clinical measures. 69% of participants in the 45 mg brepocitinib group achieved an Investigator Global Assessment (IGA) score of clear or almost clear, compared to 0% in the placebo group (P = .0047). Participants treated with brepocitinib also reported improvements in health-related quality of life, with those receiving the 45 mg dose showing a 32-point benefit over placebo on the Skindex-16, a measure of skin-related symptoms, emotions, and functioning.

The King’s Sarcoidosis Questionnaire-Skin Domain, assessing the impact of skin disease on patients’ lives, showed mean scores of 35, 29, and 2 for the brepocitinib 45-mg, 15 mg, and placebo groups, respectively. A greater proportion of patients receiving brepocitinib reported an improved overall disease state, as measured by the Patient Global Impression of Change scale.

Safety and Tolerability

The study reported a favorable safety profile for brepocitinib. Adverse events occurred in 92% of the brepocitinib 45 mg group, 55% of the 15 mg group, and 86% of the placebo group. Importantly, none of these events were classified as serious or severe, and only one participant in each treatment arm discontinued the study due to adverse events.

A Potential Turning Point for Cutaneous Sarcoidosis

Rosenbach described the results as “transformational,” highlighting the dramatic difference in response rates between the brepocitinib and placebo groups. He noted the unexpected finding of a near-zero response rate in the placebo arm, underscoring the efficacy of the drug. The preliminary safety data are also encouraging.

“These are landmark findings,” Rosenbach stated. “It is hard for me to put into words how exciting these data are.”

The positive results from the BEACON trial have paved the way for a pivotal phase 3 program, planned to begin later in 2026 following engagement with the Food and Drug Administration (FDA). Priovant Therapeutics, the developer of brepocitinib, anticipates that this larger study will confirm the efficacy and safety observed in the phase 2 trial and potentially lead to the first FDA-approved treatment for cutaneous sarcoidosis.

The potential benefits of brepocitinib may extend beyond skin manifestations, as Rosenbach suggested that a drug effective for cutaneous sarcoidosis could potentially be used to treat other organ-specific forms of the disease. What we have is based on the understanding that sarcoidosis is a systemic illness, and a successful treatment for one manifestation could have broader implications.